FDA approved FoundationOne Liquid CDx for three new companion diagnostic indications: Piqray in advanced or metastatic breast cancer; Rubraca in advanced ovarian cancer; and Alecensa in a certain type of metastatic non-small cell lung cancer.
Grail will operate as a standalone division within Illumina, currently working on readying the Galleri multi-cancer screening test for launch.
Presenting an evaluation of the GeneReader next-generation sequencing (NGS) system, the article assesses the performance of the system in comparison with an alternative NGS technology.
The Signatera test is a personalized, tumor-informed ctDNA assay optimized for molecular residual disease assessment and treatment monitoring.
Read More
The guideline includes myChoice CDx guided management in both newly diagnosed and recurrent ovarian cancer.
Read More
The use of a liquid biopsy has been shown in a 5-year clinical trial to accurately detect and monitor certain kinds of breast cancer.
Read MoreThe Oncomine Myeloid Assay GX is the first in a series of clinical research assays available from the new hematology-oncology portfolio.
Read More
A board-certified obstetrician and gynecologist expresses his concerns about the new ACS cervical cancer screening guidelines.
Read More
A tumor gene test could help identify ovarian cancer patients with predicted poor survival and inform new therapeutical approaches, study results show.
Read More
NuView Life Sciences will use the funds to complete a 600-patient in vitro double-blind clinical trial for the NV-VPAC1 cancer portfolio.
Read More
The companion diagnostic will leverage the Oncomine Precision Assay to identify non-small cell lung cancer patients with HER2 mutations.
Read More
A new study comparing four CRC screening alternatives found that annual colorectal cancer screening with Epi proColon was cost effective.
Read More
Researchers report EVPs, tiny packages of materials released by tumors, may serve as biomarkers for detecting different types of cancer with liquid biopsy.
Read More
The partnership explores models for real-time identification, patient referral, and clinical trial enrollment of patients with solid tumors and NRG1 fusion.
Read More
Medicare expanded coverage for BRACAnalysis CDx for men with prostate cancer who are eligible or may become eligible for treatment with Lynparza (olaparib).
Read More
Researchers have identified fluorescent molecules in urine that may allow patients with malignant melanoma to painlessly find out if treatment is working.
Read More
miR Scientific’s urine-based, noninvasive cancer test can detect molecular evidence of prostate cancer with sensitivity of 94% and specificity of 92%.
Read More
This is the first approval to combine two technologies—NGS and liquid biopsy—in one diagnostic in order to guide treatment decisions.
Read More